PLRX Quote, Financials, Valuation and Earnings

Bristol Myers Squibb Co. has a net margin of -- compared to Pliant Therapeutics, Inc.'s net margin of 17.96%. Pliant Therapeutics, Inc.'s return on equity of -66.1% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.

Pliant Therapeutics, Inc. has a consensus price target of $3.25, signalling upside risk potential of 168.6%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $55.09 which suggests that it could grow by 0.82%. Given that Pliant Therapeutics, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Pliant Therapeutics, Inc. is more attractive than Bristol Myers Squibb Co..

Pliant Therapeutics, Inc. has a beta of 1.291, which suggesting that the stock is 29.104% more volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.363%.

Pliant Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.54% to investors and pays a quarterly dividend of $0.62 per share. Pliant Therapeutics, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pliant Therapeutics, Inc. quarterly revenues are --, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Pliant Therapeutics, Inc.'s net income of -$26.3M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Pliant Therapeutics, Inc.'s price-to-earnings ratio is -- while Bristol Myers Squibb Co.'s PE ratio is 18.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pliant Therapeutics, Inc. is 20.40x versus 2.32x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

Cidara Therapeutics, Inc. has a net margin of -- compared to Pliant Therapeutics, Inc.'s net margin of -30201.66%. Pliant Therapeutics, Inc.'s return on equity of -66.1% beat Cidara Therapeutics, Inc.'s return on equity of -68.74%.

Pliant Therapeutics, Inc. has a consensus price target of $3.25, signalling upside risk potential of 168.6%. On the other hand Cidara Therapeutics, Inc. has an analysts' consensus of $221.50 which suggests that it could grow by 0.32%. Given that Pliant Therapeutics, Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Pliant Therapeutics, Inc. is more attractive than Cidara Therapeutics, Inc..

Pliant Therapeutics, Inc. has a beta of 1.291, which suggesting that the stock is 29.104% more volatile than S&P 500. In comparison Cidara Therapeutics, Inc. has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.073%.

Pliant Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cidara Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pliant Therapeutics, Inc. pays -- of its earnings as a dividend. Cidara Therapeutics, Inc. pays out -- of its earnings as a dividend.

Pliant Therapeutics, Inc. quarterly revenues are --, which are smaller than Cidara Therapeutics, Inc. quarterly revenues of --. Pliant Therapeutics, Inc.'s net income of -$26.3M is higher than Cidara Therapeutics, Inc.'s net income of -$83.2M. Notably, Pliant Therapeutics, Inc.'s price-to-earnings ratio is -- while Cidara Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pliant Therapeutics, Inc. is 20.40x versus 55.23x for Cidara Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Doximity, Inc. has a net margin of -- compared to Pliant Therapeutics, Inc.'s net margin of 36.83%. Pliant Therapeutics, Inc.'s return on equity of -66.1% beat Doximity, Inc.'s return on equity of 24.35%.

Pliant Therapeutics, Inc. has a consensus price target of $3.25, signalling upside risk potential of 168.6%. On the other hand Doximity, Inc. has an analysts' consensus of $67.90 which suggests that it could grow by 55.41%. Given that Pliant Therapeutics, Inc. has higher upside potential than Doximity, Inc., analysts believe Pliant Therapeutics, Inc. is more attractive than Doximity, Inc..

Pliant Therapeutics, Inc. has a beta of 1.291, which suggesting that the stock is 29.104% more volatile than S&P 500. In comparison Doximity, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pliant Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Doximity, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pliant Therapeutics, Inc. pays -- of its earnings as a dividend. Doximity, Inc. pays out -- of its earnings as a dividend.

Pliant Therapeutics, Inc. quarterly revenues are --, which are smaller than Doximity, Inc. quarterly revenues of $168.5M. Pliant Therapeutics, Inc.'s net income of -$26.3M is lower than Doximity, Inc.'s net income of $62.1M. Notably, Pliant Therapeutics, Inc.'s price-to-earnings ratio is -- while Doximity, Inc.'s PE ratio is 34.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pliant Therapeutics, Inc. is 20.40x versus 14.19x for Doximity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zymeworks, Inc. has a net margin of -- compared to Pliant Therapeutics, Inc.'s net margin of -70.99%. Pliant Therapeutics, Inc.'s return on equity of -66.1% beat Zymeworks, Inc.'s return on equity of -18.82%.

Pliant Therapeutics, Inc. has a consensus price target of $3.25, signalling upside risk potential of 168.6%. On the other hand Zymeworks, Inc. has an analysts' consensus of $35.54 which suggests that it could grow by 32.26%. Given that Pliant Therapeutics, Inc. has higher upside potential than Zymeworks, Inc., analysts believe Pliant Therapeutics, Inc. is more attractive than Zymeworks, Inc..

Pliant Therapeutics, Inc. has a beta of 1.291, which suggesting that the stock is 29.104% more volatile than S&P 500. In comparison Zymeworks, Inc. has a beta of 1.269, suggesting its more volatile than the S&P 500 by 26.869%.

Pliant Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zymeworks, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pliant Therapeutics, Inc. pays -- of its earnings as a dividend. Zymeworks, Inc. pays out -- of its earnings as a dividend.

Pliant Therapeutics, Inc. quarterly revenues are --, which are smaller than Zymeworks, Inc. quarterly revenues of $27.6M. Pliant Therapeutics, Inc.'s net income of -$26.3M is lower than Zymeworks, Inc.'s net income of -$19.6M. Notably, Pliant Therapeutics, Inc.'s price-to-earnings ratio is -- while Zymeworks, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pliant Therapeutics, Inc. is 20.40x versus 15.14x for Zymeworks, Inc.. Usually stocks with elevated PS ratios are considered overvalued.